Impact of infections and normal flora in nonhuman primates on drug development.
about
A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.Juvenile Toxicology: Relevance and Challenges for Toxicologists and PathologistsMeeting report: Spontaneous lesions and diseases in wild, captive-bred, and zoo-housed nonhuman primates and in nonhuman primate species used in drug safety studiesMolecular evolution of a malaria resistance gene (DARC) in primates.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Development of real-time PCR assays for the detection of Moraxella macacae associated with bloody nose syndrome in rhesus (Macaca mulatta) and cynomolgus (Macaca fascicularis) macaques.Clinical veterinarian's perspective of non-human primate (NHP) use in drug safety studies.Overview of known non-human primate pathogens with potential to affect colonies used for toxicity testing.Bacterial infections in cynomolgus monkeys given small molecule immunomodulatory antagonists.Simian retroviruses: infection and disease--implications for immunotoxicology research in primates.Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.Small molecule immunomodulatory drugs: challenges and approaches for balancing efficacy with toxicity.Evidence of simian retrovirus type D by polymerase chain reaction.Impact of the Genetics and Source of Preclinical Safety Animal Models on Study Design, Results, and Interpretation.Nodular lymphoid hyperplasia of the colon in a vervet monkey (Cholorocebous aethiops).Anti-Viral Drugs for Human Adenoviruses.
P2860
Q27693187-2ED745A2-7E5D-4AF8-921A-5EBFD7AEEC15Q28395679-46B85B20-8BD7-43F4-B29B-2D2155073C0AQ33667019-2602C54A-E29A-47A3-B01F-FDB144C48B38Q34259253-AC82EBB0-3143-4871-9741-72A700B32030Q35929084-54C5C6C0-85D4-44A7-A554-D4B695A9CFBDQ36613688-BB624555-025E-4BAF-91FC-CB8723C3410AQ37602198-3249935A-04A6-4309-9972-17CADB0546B1Q37631601-E0A1503D-E122-4F67-9B88-60053F8C007BQ37688092-4ED6BD22-49DF-4257-A7EC-6B9702FDE0DFQ37740153-9D0D6693-F0DC-454E-9EFC-C23C2F89CA78Q37753534-E2CB5F5F-E662-4483-BD6B-A6B94BE9809CQ37956183-BF97C6B5-EC21-429B-A7F3-8C4D0AB12C61Q38375241-E6C7DF8E-C012-46DB-BB4B-01E1FD2E1263Q38983847-94D9FC50-3ACA-4C54-B194-B1B8BF17963EQ41385208-730B87C0-0BF3-4A75-B1BE-2D3822550150Q46103262-FCC335A3-C781-4607-B6F2-AE18DA652B75
P2860
Impact of infections and normal flora in nonhuman primates on drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of infections and normal flora in nonhuman primates on drug development.
@en
Impact of infections and normal flora in nonhuman primates on drug development.
@nl
type
label
Impact of infections and normal flora in nonhuman primates on drug development.
@en
Impact of infections and normal flora in nonhuman primates on drug development.
@nl
prefLabel
Impact of infections and normal flora in nonhuman primates on drug development.
@en
Impact of infections and normal flora in nonhuman primates on drug development.
@nl
P2860
P356
P1433
P1476
Impact of infections and normal flora in nonhuman primates on drug development.
@en
P2093
Richard W Diters
Vito G Sasseville
P2860
P304
P356
10.1093/ILAR.49.2.179
P577
2008-01-01T00:00:00Z